CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.

Abstract

In a landmark article published in the May 1, 2001, issue of Clinical Cancer Research, Lee and colleagues reported the original preclinical studies demonstrating anticancer activity of BMS-247550 (ixabepilone) against taxane-sensitive and taxane-resistant cancers. Subsequent clinical trials established the clinical efficacy of ixabepilone, leading to its regulatory approval for the treatment of drug-resistant metastatic or locally advanced breast cancers.

• Authors: Navjotsingh Pabla, Alex Sparreboom
• Journal: Clinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 21 Issue 6 Pg. 1237-9 (Mar 15 2015) ISSN: 1557-3265 [Electronic] United States
• PMID: 25770292 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: ©2015 American Association for Cancer Research.

Chemical References

• Antineoplastic Agents
• Bridged-Ring Compounds
• Epothilones
• Taxoids
• Tubulin Modulators
• taxane
• ixabepilone

Topics

• Antineoplastic Agents (pharmacology)
• Breast Neoplasms (drug therapy)
• Bridged-Ring Compounds (pharmacology)
• Cell Line, Tumor
• Drug Resistance, Neoplasm
• Epothilones (pharmacology)
• Female
• HCT116 Cells
• Humans
• Microtubules (metabolism)
• Taxoids (pharmacology)
• Tubulin Modulators (pharmacology)